Literature DB >> 618978

Two tris urea mercaptoethanol extractable polypeptides found uniquely in scales of patients with psoriasis.

M P Thaler, K Fukuyama, N Inoue, D L Cram, W L Epstein.   

Abstract

This study was designed to chemically characterize the principal structural proteins of psoriatic scales. Cornified cells were obtained from 40 patients with psoriasis, 21 patients with other scaly diseases, and 13 normal individuals. Cells were washed with Tris-HCl buffer and incubated in 8 M urea containing 2-mercaptoethanol (pH 9.0) at 30 degrees C for 7 hr. Extracted proteins were subjected to SDS polyacrylamide gel electrophoresis and protein patterns from normal and diseased scales were compared. The 67,000 dalton constituent of normal cornified cells could not be identified in protein from psoriatic scale and instead, a pair of polypeptides of approximately 54,000 and 57,000 daltons appeared. These extra bands were not found in protein extractions from other skin diseases, uninvolved skin of psoriasis patients, or normal skin. In order to analyze further normal and psoriatic scale proteins, the immunoreaction of rabbit antisera to human 67,000 dalton polypeptide with extracted psoriasis protein and with frozen biopsy sections, was studied using immunoprecipitation tests and indirect immunofluorescence microscopy. Both techniques demonstrated the existence of the 67,000 dalton protein in psoriasis, but as a minor component. These results indicate that additional unique urea mercaptoethanol soluble proteins are formed in psoriatic lesions, and this unusual protein synthesis may reflect the morphological changes in this disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 618978     DOI: 10.1111/1523-1747.ep12543461

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Abnormal fibrous protein isolated from the stratum corneum of a patient with bullous congenital ichthyosiform erythroderma (BCIE).

Authors:  H Ogawa; M Hattori; Y Ishibashi
Journal:  Arch Dermatol Res       Date:  1979-10       Impact factor: 3.017

2.  Intermediates in the conversion of prekeratin into keratin molecules in psoriatic epidermis.

Authors:  Y Katagata; K Aso
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

3.  Effect of crude coal tar in the mouse-tail model of psoriasis.

Authors:  P T Bladon; M Taylor; E J Wood; W J Cunliffe
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

4.  Flow cytometric analysis of epidermal subpopulations from normal and psoriatic skin using monoclonal antibodies against intermediate filaments.

Authors:  P E van Erp; J J Rijzewijk; J B Boezeman; J Leenders; S de Mare; J Schalkwijk; P C van de Kerkhof; F C Ramaekers; F W Bauer
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

5.  Intracellular keratins in normal and pathological bronchial mucosa. Immunocytochemical studies on biopsies and cell suspensions.

Authors:  F Bejui-Thivolet; J Viac; J Thivolet; M Faure
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

6.  Keratin polypeptide profile in psoriatic epidermis normalized by treatment with etretinate (aromatic retinoid Ro 10-9359).

Authors:  M J Staquet; M R Faure; A Reano; J Viac; J Thivolet
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

7.  Experimental production of antibodies against stratum corneum keratin polypeptides.

Authors:  J Viac; M J Staquet; J Thivolet; C Goujon
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

8.  Expression of common cytoplasmic antigens by epithelial cells of thymus and epidermis.

Authors:  J Viac; D Schmitt; A Reano; J Thivolet
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

9.  Monoclonal antibody analysis of keratin expression in epidermal diseases: a 48- and 56-kdalton keratin as molecular markers for hyperproliferative keratinocytes.

Authors:  R A Weiss; R Eichner; T T Sun
Journal:  J Cell Biol       Date:  1984-04       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.